TransCode Therapeutics:
​A Clinical-Stage Oncology Company
​Focused on Treating Metastatic Disease

Lead Therapeutic Candidate - TTX-MC138

Targeting microRNA-10b - master regulator of metastasis

TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer, an area traditionally overlooked because, from a therapeutic perspective, non-metastatic and metastatic tumor cells are often viewed as being the same. However, despite significant efforts made in the past several years to decipher the genetic structure of primary tumors, there has been relatively limited attention given to comprehending the genetic makeup of metastatic tumors.
  • Small, non-coding strands of RNA (microRNAs) have been identified as a significant player in the pathology of cancer and metastasis
  • Our research observed that miRNA-10b acts as a master regulator of the viability of metastatic tumor cells
  • miRNA-10b is shown to be largely dispensable for normal development but critical to tumorigenesis
  • Our competitive advantage derives from years of work to deliver oligonucleotides (synthetic RNA)  to cancer cells, a decades long challenge in the market
  • The iron oxide nanoparticle delivery platform, TTX, is highly tunable to pre-designed specifications to deliver therapeutic candidates to targets in tumors and metastases 
  • Treatment with TTX-MC138 has led to durable regression of established metastases in murine models of metastatic breast cancer and pancreatic cancer
  • miRNA-10b has been shown to have broad applicability across over 18 + cancer types  including breast, pancreatic, ovarian and colon cancer, glioblastomas and others
  • TTX-MC138 is hormone receptor independent and has the potential to treat metastatic breast cancer regardless of type (ER+/-, PR+/, HER2+/-, or combinations thereof)
​TransCode's promising therapeutic strategy relies on specific eradication of metastatic tumor cells– cells that have evolved from the primary tumor to escape into the circulation, survive during transit, and colonize distant organs.
​TTX-MC138, our lead therapeutic candidate,  has been shown to inhibit microRNA-10b
​resulting in regression of disease without recurrence in pre-clinical studies.
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

​MISSION
​CLINICAL TRIALS

About

​METASTATIC DISEASE
TTX-MC138
​SCIENCE
​PIPELINE
​DELIVERY PLATFORM
​OTHER PRODUCTS
​LEADERSHIP

Publications

​PUBLICATIONS
© TRANSCODE THERAPEUTICS, INC. 2023.​ ALL RIGHTS RESERVED.